Yingxi Intelligent (英矽智能) $2.75 Billion Tie‑up with Eli Lilly (礼来) Rekindles the Oral GLP‑1 Race

Deal and immediate stakes

Yingxi Intelligent (英矽智能, 3696.HK), the Beijing‑based AI drug‑discovery biotech, announced a strategic collaboration with Eli Lilly (礼来) worth up to $2.75 billion. Under the agreement Lilly will pay a $115 million upfront fee for an exclusive global license to a preclinical candidate described by Yingxi as having “best‑in‑class” potential, and the partners will co‑develop additional targets chosen by Lilly. If development, regulatory and commercial milestones are met, Yingxi stands to receive roughly $2.635 billion more plus tiered royalty payments. It has been reported that earlier market chatter even suggested a Lilly acquisition; reportedly, the transaction required review under U.S. HSR rules and scrutiny by the FTC.

Why the market thinks GLP‑1

Public pipeline disclosures and market signals point to the licensed asset targeting the GLP‑1 receptor in metabolic disease — the hottest battleground in global biopharma. Oral GLP‑1s aim to capture patients who prefer pills over injections, and weekly dosing would be a further competitive edge. Reportedly, Lilly’s own Orforglipron and Novo Nordisk’s oral semaglutide have already reset expectations for efficacy and prescribing patterns, while analysts at Goldman Sachs forecast oral GLP‑1s will make up a growing portion of the weight‑loss market through 2035. For Lilly, adding a candidate that could extend dosing frequency to weekly would round out a product matrix spanning injectables and daily oral drugs.

Milestones, reality checks and track record

Big headline numbers come with known delivery risks. It has been reported that many large biotech licensing deals pay out little of headline totals: third‑party analyses show low milestone realization rates across the industry, and historical data suggest the bulk of announced payments often depend on winning late‑stage clinical achievements. Yingxi’s management — founder Alex Zhavoronkov and co‑founder/CSO Ren Feng (任峰) — acknowledge the uncertainty, saying they expect 60–70% probability of milestone achievement for the selected program while pointing to prior out‑licensing wins (Exelixis, Menarini) where preclinical assets progressed to clinical milestones.

Strategic implications for Yingxi and the sector

For Yingxi, the deal is both technical validation of its AI‑driven discovery platform and a liquidity milestone that reshapes its revenue mix: its first post‑IPO annual report shows drug‑discovery and pipeline development now account for nearly equal shares of revenue. The company says it will keep focusing on BD deals rather than selling out — Alex argued a sale would undervalue the platform and that strategic acquirers might more likely be big tech firms than traditional pharmas. The bigger question remains: can AI‑native biotechs translate high‑profile BD paydays into sustained clinical execution and real commercial products? If this Lilly tie‑up delivers, it will be a major proof point for the AI+biotech model; if it falters, it will also serve as a reminder of the long, risky road from algorithm to approved medicine.